

---

**Molekularne diagnostične preiskave in vitro - Specifikacije za predpreiskovalne procese pri aspiraciji s tanko iglo (FNA) - 3. del: Iz genoma izolirana DNK**

Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for Fine Needle Aspirates (FNAs) - Part 3: Isolated genomic DNA

Molekularanalytische in vitro diagnostische Verfahren - Spezifikationen für präanalytische Prozesse für Feinnadelaspirate - Teil 3: Isolierte genomische DNA

Analyses moléculaires de diagnostic in vitro - Spécifications pour les processus préanalytiques pour les ponctions à l'aiguille fine - Partie 3: ADN génomique isolé

[SIST-TS CEN/TS 17688-3:2022](http://standards.iteh.ai/catalog/standards/sist/d0906598-5fef-43c1-ae54-fd979567a1e4/sist-ts-cen-ts-17688-3-2022)  
**Ta slovenski standard je istoveten z: CEN/TS 17688-3:2021**

**ICS:**

11.100.10	Diagnostični preskusni sistemi in vitro	In vitro diagnostic test systems
-----------	---	----------------------------------

**SIST-TS CEN/TS 17688-3:2022****en,fr,de**

**iTeh STANDARD  
PREVIEW  
(standards.iteh.ai)**

SIST-TS CEN/TS 17688-3:2022

<https://standards.iteh.ai/catalog/standards/sist/d00b0598-5fef-43c1-ae54-fd979567a1e4/sist-ts-cen-ts-17688-3-2022>

TECHNICAL SPECIFICATION  
SPÉCIFICATION TECHNIQUE  
TECHNISCHE SPEZIFIKATION

**CEN/TS 17688-3**

December 2021

ICS 11.100.10

English Version

**Molecular in vitro diagnostic examinations - Specifications  
for pre-examination processes for Fine Needle Aspirates  
(FNAs) - Part 3: Isolated genomic DNA**

Analyses moléculaires de diagnostic in vitro -  
Spécifications pour les processus préanalytiques pour  
les ponctions à l'aiguille fine - Partie 3: ADN génomique  
isolé

Molekularanalytische in-vitro-diagnostische Verfahren  
- Spezifikationen für präanalytische Prozesse für  
Feinnadelaspirate - Teil 3: Isolierte genomische DNA

This Technical Specification (CEN/TS) was approved by CEN on 15 November 2021 for provisional application.

The period of validity of this CEN/TS is limited initially to three years. After two years the members of CEN will be requested to submit their comments, particularly on the question whether the CEN/TS can be converted into a European Standard.

CEN members are required to announce the existence of this CEN/TS in the same way as for an EN and to make the CEN/TS available promptly at national level in an appropriate form. It is permissible to keep conflicting national standards in force (in parallel to the CEN/TS) until the final decision about the possible conversion of the CEN/TS into an EN is reached.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.

<https://standards.iteh.ai/catalog/standards/sist/d00b0598-5fef-43c1-ae54-fd979567a1e4/sist-ts-cen-ts-17688-3-2022>



EUROPEAN COMMITTEE FOR STANDARDIZATION  
COMITÉ EUROPÉEN DE NORMALISATION  
EUROPÄISCHES KOMITEE FÜR NORMUNG

**CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels**

<b>Contents</b>	<b>Page</b>
European foreword.....	4
Introduction .....	5
1 Scope.....	6
2 Normative references.....	6
3 Terms and definitions .....	6
4 General considerations.....	12
5 Outside the laboratory .....	13
5.1 Specimen collection.....	13
5.1.1 General.....	13
5.1.2 Information about the patient/specimen donor .....	14
5.1.3 Information about the specimen.....	14
5.1.4 Selection of the primary FNA collection devices.....	14
5.1.5 FNA specimen collection and stabilization from the donor/patient.....	14
5.2 Specimen storage and transport.....	16
6 Inside the laboratory .....	16
6.1 Specimen reception.....	16
6.2 Specimen/sample storage after transport and reception.....	17
6.2.1 General.....	17
6.2.2 Storage of FNA specimen/samples with stabilizer .....	17
6.2.3 Storage of FNA specimen/samples using collection devices without stabilizers .....	17
6.3 Specimen/sample processing for cytological examination prior to gDNA isolation.....	18
6.3.1 General.....	18
6.3.2 Handling of cell suspension.....	18
6.3.3 Preparation of paraffin-embedded cell blocks.....	19
6.3.4 Preparation of cell suspension slides.....	20
6.4 Evaluation of the pathology of the specimen or sample(s).....	21
6.5 Processed sample storage, transport and reception.....	21
6.5.1 General.....	21
6.5.2 Storage and transport of cell suspension .....	21
6.5.3 Storage and transport of paraffin-embedded cell blocks.....	21
6.5.4 Storage and transport of cell suspension slides .....	22
6.6 Isolation of gDNA.....	22
6.6.1 General.....	22
6.6.2 Using a commercial gDNA isolation kit intended for diagnostic use.....	23
6.6.3 Using the laboratory's own gDNA isolation procedure.....	23
6.6.4 Isolation of gDNA from specific sample types.....	23
6.7 Quantity and quality assessment of isolated gDNA .....	24
6.7.1 General.....	24
6.7.2 Quantity assessment.....	25
6.7.3 Quality assessment.....	25
6.8 Storage of isolated gDNA .....	25
6.8.1 General.....	25
Annex A (informative) Impact of pre-analytical variables on FNA sample quality, gDNA quantity and quality.....	27

<b>A.1</b>	<b>Introduction.....</b>	<b>27</b>
<b>A.2</b>	<b>Method - FNA model sample .....</b>	<b>27</b>
<b>A.3</b>	<b>Result - Impact of specimen stabilization method on FNA cell quality .....</b>	<b>28</b>
<b>A.3.1</b>	<b>General .....</b>	<b>28</b>
<b>A.3.2</b>	<b>Method.....</b>	<b>28</b>
<b>A.3.3</b>	<b>Result/conclusion.....</b>	<b>31</b>
<b>A.4</b>	<b>Impact of stabilization and storage duration on quantity and quality of isolated gDNA.....</b>	<b>31</b>
	<b>Bibliography .....</b>	<b>35</b>

**iTeh STANDARD  
PREVIEW  
(standards.iteh.ai)**

SIST-TS CEN/TS 17688-3:2022

<https://standards.iteh.ai/catalog/standards/sist/d00b0598-5fef-43c1-ae54-fd979567a1e4/sist-ts-cen-ts-17688-3-2022>

**CEN/TS 17688-3:2021 (E)****European foreword**

This document (CEN/TS 17688-3:2021) has been prepared by Technical Committee CEN/TC 140 “In vitro diagnostic medical devices”, the secretariat of which is held by DIN.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

Any feedback and questions on this document should be directed to the users’ national standards body. A complete listing of these bodies can be found on the CEN website.

According to the CEN/CENELEC Internal Regulations, the national standards organisations of the following countries are bound to announce this Technical Specification: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

**iTeh STANDARD  
PREVIEW  
(standards.iteh.ai)**

SIST-TS CEN/TS 17688-3:2022

<https://standards.iteh.ai/catalog/standards/sist/d00b0598-5fef-43c1-ae54-fd979567a1e4/sist-ts-cen-ts-17688-3-2022>

## Introduction

Molecular *in vitro* diagnostics has enabled significant progress in medicine. Further progress is expected by new technologies analysing profiles of nucleic acids, proteins, and metabolites in human tissues and body fluids. However, the profiles of these molecules can change drastically during the pre-examination process, including the specimen collection, transport, storage and processing.

Examination of genomic DNA (gDNA) is commonly used in clinical practice. This includes e.g. prognostic and predictive biomarker examinations. This is a fast growing field in molecular diagnostics.

Fine needle aspiration is a non-surgical procedure that uses a thin, hollow-bore needle and syringe to collect a specimen from patients for cytopathological and molecular investigation. As a minimally-invasive technique, fine needle aspirates (FNAs) are commonly used to diagnose and monitor for example a range of cancer types e.g. breast, lung and thyroid cancer, and other diseases, such as inflammatory diseases. FNAs also provide the opportunity to sample metastatic sites (e.g. lymph nodes) and otherwise non-resectable tissues.

Besides cytological assessment, molecular biological analysis of FNAs is expected to become increasingly used for cancer and other disease diagnostics, including companion diagnostics.

One of the challenges facing molecular analysis of FNA samples is their small size and diversity in composition (cells, blood, body fluid). The low cellular content of FNAs means that the yield of isolated gDNA is typically towards the lower end of detection for molecular examination. Therefore, the gDNA isolation procedure should provide a sufficient amount of gDNA as required by the specific examination.

After specimen collection, gDNA can fragment and degrade by e.g. fixation, processing and storage. Additionally, chemical modifications introduced into gDNA during FNA fixation might lead to sequence alterations or changes in the methylation status. The described changes of the gDNA molecules can impact the validity, reliability and sensitivity of the examination results.

Therefore, standardization of the entire process from specimen collection to gDNA examination is needed to minimize gDNA changes introduced by e.g. degradation, fragmentation and modification after FNA collection. This document describes special measures which need to be taken to obtain good quality FNA specimens/samples and isolated gDNA therefrom for molecular examination.

In this document, the following verbal forms are used:

- “shall” indicates a requirement;
- “should” indicates a recommendation;
- “may” indicates a permission;
- “can” indicates a possibility or a capability.

## CEN/TS 17688-3:2021 (E)

## 1 Scope

This document gives guidelines on the handling, documentation, storage and processing of fine needle aspirates (FNAs) intended for gDNA examination during the pre-examination phase before a molecular examination is performed.

This document is applicable to molecular *in vitro* diagnostic examinations including laboratory developed tests performed by medical laboratories and molecular pathology laboratories that examine gDNA isolated from FNAs. It is also intended to be used by laboratory customers, *in vitro* diagnostics developers and manufacturers, biobanks, institutions and commercial organisations performing biomedical research, and regulatory authorities.

Different dedicated measures are taken for collecting, stabilizing, transporting and storing of core needle biopsies (FNA Biopsy or FNA B) and are not covered in this document, but EN ISO 20184-3, *Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for frozen tissue — Part 3: Isolated DNA* and EN ISO 20166-3, *Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue — Part 3: Isolated DNA*.

This document is not applicable for pathogen DNA examination and gDNA examination by *in situ* detection.

NOTE International, national or regional regulations or requirements can also apply to specific topics covered in this document.

## 2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

EN ISO 15189, *Medical laboratories — Requirements for quality and competence (ISO 15189)*

## 3 Terms and definitions

For the purposes of this document, the terms and definitions given in EN ISO 15189 and the following apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

**3.1 aliquot**  
portion of a larger amount of homogenous material, assumed to be taken with negligible sampling error

Note 1 to entry: The term is usually applied to fluids. Tissues are heterogeneous and therefore cannot be aliquoted.

Note 2 to entry: The definition is derived from the Compendium of Chemical Terminology Gold Book. International Union of Pure and Applied Chemistry. Version 2.3.3, 2014; the PAC, 1990,62,1193 (Nomenclature for sampling in analytical chemistry (Recommendations 1990)) p. 1206; and the PAC 1990, 62, 2167 (Glossary of atmospheric chemistry terms (Recommendations 1990)) p. 2173.



**3.2****ambient temperature**

unregulated temperature of the surrounding air

[SOURCE: EN ISO 20166-1:2018, 3.2]

**3.3****analyte**

component represented in the name of a measurable quantity

[SOURCE: ISO 17511:2020, 3.2, modified — Deleted example.]

**3.4****analytical test performance****analytical performance**

accuracy, precision, and sensitivity of a test to measure the analyte of interest

Note 1 to entry: Other test performance characteristics such as robustness, repeatability can apply as well.

[SOURCE: EN ISO 20184-1:2018, 3.4]

**3.5****biomolecule**

organic molecule produced by living organisms that is involved in the maintenance and metabolic processes of organisms

Note 1 to entry: Examples of organic molecules are protein, carbohydrate, lipid, or nucleic acid.

**3.6****cell block**

paraffin-embedded cell clot

[SIST-TS CEN/TS 17688-3:2022](https://standards.iteh.ai/catalog/standards/sist/d00b0598-5fef-43c1-ae54-fd979567a1e4/sist-ts-cen-ts-17688-3-2022)

<https://standards.iteh.ai/catalog/standards/sist/d00b0598-5fef-43c1-ae54-fd979567a1e4/sist-ts-cen-ts-17688-3-2022>

**3.7****cell clot**

cell-rich liquid specimen/sample concentrated into a compact cell aggregate for subsequent processing

**3.8****closed system**

non-modifiable system provided by the vendor including all necessary components for the analysis (i.e., hardware, software, procedures and reagents)

**3.9****cyto centrifugation**

cytology method that is specifically designed to concentrate cells on a slide by centrifugation

**3.10****deoxyribonucleic acid****DNA**

polymer of deoxyribonucleotides occurring in a double-stranded (dsDNA) or single-stranded (ssDNA) form

[SOURCE: EN ISO 22174:2005, 3.1.2]

## CEN/TS 17688-3:2021 (E)

## 3.11

**deoxyribonuclease****DNase**

enzyme that catalyses the degradation of DNA into smaller components

## 3.12

**diagnosis**

identification of a disease from its signs and symptoms, where the diagnostic process can involve examinations and tests for classification of an individual's condition into separate and distinct categories or subclasses that allow medical decisions about treatment and prognosis to be made

[SOURCE: EN ISO 20166-1:2018, 3.7]

## 3.13

**examination****analytical test**

set of operations with the objective of determining the value or characteristics of a property

Note 1 to entry: Processes that include all kinds of parameter testing or chemical manipulation for quantitative or qualitative examination.

[SOURCE: EN ISO 15189:2012, 3.7, modified — Notes to entry 1 to 3 have been removed. Note 1 to entry has been added and “analytical test” has been added as a preferred term.]

## 3.14

**examination manufacturer****analytical test manufacturer**

entity that manufactures and/or produces a specific analytical test

## 3.15

**examination performance****analytical test performance****analytical performance**

accuracy, precision, and sensitivity of a test to measure the analyte of interest

Note 1 to entry: Other test performance characteristics such as robustness, repeatability can apply as well.

[SOURCE: EN ISO 20184-1:2018, 3.4]

## 3.16

**fixative**

solution used to preserve or harden FNA specimens for microscopic and molecular examination

## 3.17

**formalin**

saturated aqueous formaldehyde solution which at 100 % contains 37 % formaldehyde by mass (corresponding to 40 % by volume)

[SOURCE: EN ISO 20166-1:2018, 3.11]

## 3.18

**fine needle aspirate****FNA**

specimen withdrawn by a non-operative procedure that uses a thin, hollow-bore needle

**3.19****FNA primary collection device**

thin, hollow-bore needle or syringe used for collecting the FNA specimen from the donor/patient

**3.20****FNA secondary collection device**

suitable container into which the specimen is transferred from the FNA primary collection device

**3.21****genomic DNA****gDNA**

chromosomal DNA, in contrast to extra-chromosomal DNAs such as mitochondrial DNA

**3.22****homogeneous**

uniform in structure and composition

[SOURCE: EN ISO 20166-1:2018, 3.31]

**3.23****interfering substances**

endogenous substances of a specimen/sample or exogenous substances that can alter an examination result

Note 1 to entry: Examples of endogenous substances include blood components in the FNA specimen.

Note 2 to entry: Examples of exogenous substances include compounds of stabilization solutions.

**3.24****laboratory developed procedure**

modified commercially available *in vitro* diagnostic device or fully in house developed procedure

**3.25****paraffin embedding**

process in which a sample is placed in paraffin to generate a hard surrounding matrix so that thin microscopic sections can be cut

## CEN/TS 17688-3:2021 (E)

## 3.26

**pre-examination process****pre-analytical workflow****pre-analytical phase****pre-examination phase**

process that starts, in chronological order, from the clinician's request and includes the examination request, preparation and identification of the patient, collection of the primary sample(s), transportation to and within the analytical laboratory, isolation of analytes, and ends when the analytical examination begins

Note 1 to entry: The pre-examination phase includes preparative processes that influence the outcome of the intended examination.

[SOURCE: EN ISO 15189:2012, 3.15, modified — An additional term was added and more detail was included.]

## 3.27

**primary sample****specimen**

discrete portion of a body fluid, breath, hair or tissue taken for examination, study or analysis of one or more quantities or properties assumed to apply for the whole

[SOURCE: EN ISO 15189:2012, 3.16, modified — The term and definition is used here without the original notes.]

## 3.28

**proficiency test**

evaluation of participant performance against pre-established criteria by means of inter-laboratory comparisons

[SOURCE: EN ISO/IEC 17043:2010, 3.7, modified — Term and definition are used here without the original notes.]

## 3.29

**ribonucleic acid****RNA**

polymer of ribonucleotides occurring in a double-stranded or single-stranded form

[SOURCE: EN ISO 22174:2005, 3.1.3]

## 3.30

**ribonuclease****RNase**

enzyme that catalyses the degradation of RNA into smaller components

## 3.31

**room temperature**

temperature in the range of 18 °C to 25 °C

Note 1 to entry: Local or national regulations can have different definitions.

[SOURCE: EN ISO 20166-1:2018, 3.22]